Bangalore-based drugmaker Biocon, is developing its own version of Novo Nordisk's wildly popular weight-loss drug Wegovy in a bid to be a part of the exploding obesity treatment market that is forecast to reach at least $100 billion by 2030. The company's CEO Siddharth Mittal said they aim to be...
India’s Biocon Approved for the First Generic Version of liraglutide Injectible
Headquartered in Bangalore, Biocon Ltd, a leading Indian pharmaceutical company, is positioning itself in the weight loss drug market as patents for some blockbuster obesity medications are set to expire. The company has secured approval from the UK's regulatory authority for the first generic version of liraglutide, an injectable drug...
India’s Biocon Acquires Eywa Pharma of New Jersey
Bangalore headquartered biopharmaceutical company, Biocon Ltd., announced that its step-down, wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufacturing facility, located in Cranbury, New Jersey, effective 1st September, 2023. The facility was acquired for a total consideration $7.7 million. As part of the acquisition, the...
Biocon Partners with Zentiva for Commercialization of Liraglutide in EU
India's Biocon Limited, signed a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity. Under the terms of this agreement, Biocon will be responsible...